Sangamo Therapeutics Aktie
WKN: 936386 / ISIN: US8006771062
|
24.06.2025 14:43:17
|
Sangamo Therapeutics Reports Positive Data From Phase 1/2 STAAR Study In Fabry Disease
(RTTNews) - Sangamo Therapeutics, Inc. (SGMO) Tuesday reported positive topline results from the registrational Phase 1/2 STAAR study of its gene therapy candidte isaralgagene civaparvovec for the treatment of Fabry disease.
Fabry disease, is a rare genetic disorder that can affect many parts of the body.
Following a single dose of isaralgagene civoparvovec, a positive mean annualized eGFR (estimated Glomerular Filtration Rate) slope of 1.965 mL/min/1.73m2/year at 52-weeks was observed across all 32 dosed patients in the study, which the U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval.
Sangamo intends to submit a Biologics License Application (BLA) in 2026.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sangamo Therapeutics Incmehr Nachrichten
Analysen zu Sangamo Therapeutics Incmehr Analysen
Aktien in diesem Artikel
| Sangamo Therapeutics Inc | 0,48 | -3,52% |
|